Amgen Bags Onyx For $10.4B After Quick Chase
Amgen will launch a tender offer for San Francisco-based Onyx, which focuses on rare and hard-to-treat cancers. The merger will boost Amgen's fast-growing oncology portfolio and give Onyx the cash and marketing oomph for new drugs to treat blood and thyroid cancer.
"We believe that Amgen is ideally suited to realize the full potential...
Already a subscriber? Click here to login